Survival with lung cancer in Finland has not improved during 2007–2019–a single center retrospective population-based real-world study

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Pitkäniemi J, Malila N, Tanskanen T, et al. Cancer in Finland 2019. Cancer society of Finland publication no. 98. Helsinki: Cancer Society of Finland; 2021.
   Google Scholar
• Ruokolainen O, Heloma A, Jousilahti P, et al. Thirty-eight-year trends of educational differences in smoking in Finland. Int J Public Health. 2019;64(6):853–860.
   PubMed Web of Science ®Google Scholar
• Memmott RM, Wolfe AR, Carbone DP, et al. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol. 2021;16(7):1086–1098.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
   PubMed Web of Science ®Google Scholar
• Britschgi C, Addeo A, Rechsteiner M, et al. Real-world treatment patterns and survival outcome in advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer patients. Front Oncol. 2020;10:1299.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, di Carlo V, et al. Global surveillance of trends in cancer survival 2000–2014 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Solberg S, Nilssen Y, Brustugun OT, et al. Increase in curative treatment and survival of lung cancer in Norway 2001–2016. Eur J Epidemiol. 2019;34(10):951–955.
   PubMed Web of Science ®Google Scholar
• Snee M, Cheeseman S, Thompson M, et al. Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology Database Analysis from the I-O optimise initiative. BMJ Open. 2021;11(9):e046396.
   PubMed Web of Science ®Google Scholar
• Mäkitaro R, Pääkko P, Huhti E, et al. Prospective population-based study on the survival of patients with lung cancer. Eur Respir J. 2002;19(6):1087–1092.
   PubMed Web of Science ®Google Scholar
• Gunn J, Valo J, Sipilä J, et al. Trends and results of lung cancer surgery in Finland between 2004 and 2014. Eur J Cardiothorac Surg. 2018;54(1):127–133.
   PubMed Web of Science ®Google Scholar
• Helminen O, Valo J, Andersen H, et al. Extended resections and other special cases in lung cancer surgery: real-world population-based outcomes. Thorac Cancer. 2020;11(10):2932–2940.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Lehtonen J, Lehtovirta J, Mäkelä-Bengs P. THL-Toimenpideluokitus—THL-Åtgärdskalssifikation. Helsinki (Finland): THL; 2013.
   Google Scholar
• Sobin L, Wittekind C. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
   Google Scholar
• Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Chichester (UK): John Wiley & Sons, Ltd; 2009.
   Google Scholar
• Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 8th ed. Chichester (UK): John Wiley & Sons, Ltd; 2017.
   Google Scholar
• Official Statistics of Finland. Population structure (e-publication). Helsinki: Statistics Finland; 2023.
   Google Scholar
• Alexander M, Wolfe R, Ball D, et al. Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer. 2017;117(5):744–751.
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv192–iv237.
   PubMed Web of Science ®Google Scholar
• Ekman S, Horvat P, Rosenlund M, et al. Epidemiology and survival outcomes for patients with NSCLC in Scandinavia in the preimmunotherapy era: a SCAN-LEAF retrospective analysis from the I-O optimise initiative. JTO Clin Res Rep. 2021;2(5):100165.
   PubMedGoogle Scholar
• Aarts MJ, van den Borne BE, Biesma B, et al. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy. Int J Cancer. 2015;136(5):E387–E395.
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
   PubMed Web of Science ®Google Scholar
• De Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513.
   PubMed Web of Science ®Google Scholar
• Pedersen JH, Sorensen JB, Saghir Z, et al. Implementation of lung cancer CT screening in the Nordic countries. Acta Oncol. 2017;56(10):1249–1257.
   PubMed Web of Science ®Google Scholar
• Casal-Mouriño A, Valdés L, Barros-Dios JM, et al. Lung cancer survival among never smokers. Cancer Lett. 2019;451:142–149.
   PubMed Web of Science ®Google Scholar